Chicago Lymphoma Symposium 2022 Abstracts

Title

PDF File

Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data

Impact of cachexia at apheresis and infusion on post-CAR-T cell therapy outcomes in aggressive lymphoma
End of Treatment peripheral blood TCR evaluation for minimal residual disease evaluation in Peripheral T-cell Lymphomas
Pre-anthracycline left ventricular ejection fraction (LVEF) assessment and long-term cardiovascular (CV) outcomes in adolescent & young adult (AYA) lymphoma survivors
Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma
Phase 1/2 Trial of Bispecific LV20.19 CAR T-cells for Relapsed, Refractory (R/R) Mantle Cell Lymphoma
Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era: A follow-up analysi
A Case of Angioimmunoblastic Lymphoma Presenting as Airway Obstruction
Renal Tubulopathy associated with Cytokine Release Syndrome after CD-19 CAR T Cell therapy in a patient with refractory DLBCL
Alliance A059102: A Randomized Phase II US Intergroup Study of CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P in Previously Untreated CD30 Negatrive Perhpheral T-cell Lymphomas (PTCL)
A multicenter, single-arm, phase I/II dose finding and efficacy study of venetoclax, CC-486, and obinutuzumab in minimally-pretreated follicular lymphoma

ABSTRACTS SUBMISSION OPEN: December 30, 2021
ABSTRACTS CLOSE: March 25, 2022
ABSTRACTS ANNOUNCED: April 8, 2022

Abstract Submission Guidelines

Word count: 700 (inclusive of title and abstract text) Font: Arial; Font Size: 11 The suggested structure is outlined below; however, it is not required: Introduction, Methods, Results, Conclusions
  • Multiple paragraphs are permitted.
  • Do not use bold or underline formatting; italics are permitted.
  • Use numerals to indicate numbers unless they are at the beginning of a sentence.
  • References are to be cited within the text, not as footnotes.
  • Figures and tables are not included in the text count and must be uploaded as separate files. See below for file guidelines.
  • Please ensure any symbols are viewable and accurate after entering your abstract.
Title
  • The title should objectively describe the study.
  • The title Should be in sentence case.
  • Please use generic names rather than proprietary drug names.
  • Keep in mind, the title should not allude to a result or conclusion of the study.
Abstract type
  • All types of clinic-based and laboratory-based research projects relating lymphoma are eligible for submission.     
    • If a clinical trial, indicate if the trial has been registered, the registry, and the registration number.
  • Figures and Tables
    • Figures and tables must be submitted as images and thus do not count towards the character count limit.
    • Files should be shared as jpeg, png, or gif. PDF and TIF files are NOT permitted.

Abstract Submission Guidelines

Abstracts should be submitted to iucls@bioascend.com by Friday, March 25, 2022.

Please direct any questions regarding abstracts to iucls@bioascend.com